Sameer Kotak

TL;DR: Early identification and treatment of patients with glaucoma and those with ocular hypertension at high risk of developing vision loss are likely to reduce an individual's loss of health-related quality of life as well as the personal and societal economic burdens.

TL;DR: It is demonstrated for the first time in Europe that resource utilisation and direct medical costs of glaucoma management increase with worsening disease severity.

TL;DR: A glaucoma treatment that delays the progression of disease could have the potential to significantly reduce the health economic burden of this chronic disease over many years.

TL;DR: Although patients with non-radiographic axSpA have shorter disease duration and lack radiological changes, they demonstrate a substantial burden of illness, with self-reported disease activity and functional impairments comparable to those found in patients with radiographic disease.

TL;DR: Patients without ADA generally showed numerically better clinical outcomes than those with ADA, and there were negative correlations between trough drug levels and both CRP and ESR in ADL- and IFX-treated patients.